缬沙坦对伴有高血压病的代谢综合征患者血管性假血友病因子的影响
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2009年第1期
- 页码:
- 73
- 栏目:
- 临床研究
- 出版日期:
- 2009-02-28
文章信息/Info
- Title:
- Effect of valsartan on the level of vWF in patients with hypertension and metabolic syndrome
- Author(s):
- GAO Jia-er; JIN Zheng-ming; ZHOU Fen; SUN Jian; ZHU Zhao-hui; HU Shen-jiang
- Department of Cardiology, First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou 310003, Zhejiang, China
- Keywords:
- valsartan; hypertension; essential; metabolic syndrome; von Willebrand factor; endothelial function
- 分类号:
- R589；R972.14
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 目的 观察伴有高血压病的代谢综合征（metabolic syndrome，MS）患者血浆血管性假血友病因子（von Willebrand factor,vWF）水平及应用缬沙坦后vWF的变化。方法 测定22例伴有高血压病的MS患者服用缬沙坦80 mg/d4周前后及29例健康体检者血浆vWF含量。结果 伴高血压病的MS患者血浆vWF显著高于健康对照者［(176±24)% vs (130±26)%，P<0.01］；vWF含量与收缩压（SBP）［r＝0.60，P<0.01］、舒张压（DBP）［r＝0.57，P<0.01］、平均动脉压（MAP）［r＝0.61，P<0.01］、体质量指数（BMI）［r＝0.53，P<0.01］、三酰甘油（TG）［r=0.36，P<0.05］、总胆固醇（TC）［r=0.49，P<0.01］、空腹血糖（FBG）［r＝0.45，P<0.01］呈正相关；缬沙坦治疗4周后，伴高血压病的MS患者血浆vWF水平较治疗前显著降低［(160±15)% vs (176±24)%，P<0.01］。结论 伴高血压病的MS患者血浆vWF水平较健康人明显增高；予缬沙坦治疗后，在有效降低血压的同时，可短期内降低vWF水平，改善血管内皮功能。
- Abstract:
- AIM To observe the plasma level of von Willebrand factor (vWF) in patients with hypertension and metabolic syndrome (MS) and to measure the changes of vWF after valsartan administration. METHODS The plasma level of vWF was determined in 22 hypertensive patients with MS before and after valsartan at a dose of 80 mg once daily for 4 weeks and in 29 healthy objects. RESULTS The plasma level of vWF in patient group was significantly higher than that in the control group ［(176±24)% vs (130±26)%, P<0.01］. The plasma level of vWF had positive correlation with SBP （r＝0.60, P<0.01）, DBP(r＝0.57, P<0.01), MAP(r＝0.61, P<0.01), BMI（r＝0.53, P<0.01）, TG(r＝0.36, P<0.05), TC(r=0.49, P<0.01) and FBG（r＝0.45, P<0.01）. After 4 weeks’ treatment with valsartan, the plasma vWF in patients with hypertension and MS diminished significantly ［(160±15)% vs (176±24)%, P<0.01］. CONCLUSION The plasma level of vWF in patients with MS and hypertension is significantly higher. Valsartan not only controls the blood pressure but also decreases the plasma vWF in a short-term treatment and improves the endothelial function.
参考文献/References
[1］ Klein BE, klein R, Lee KE. Components of the metabolic syndrome and the risk of cardiovascular disease and diabetes in Beaver Dam［J］． Diabetes Care, 2002, 25(10):1790-1794.［2］ 中国高血压防治指南修订委员会(刘力生). 2004 年中国高血压防治指南(实用本)［J］. 中华心血管病杂志， 2004， 32(12)：1060-1064.［3］ 中华医学会糖尿病学分会.关于代谢综合征的建议［J］. 中华糖尿病杂志， 2004， 12(3)：156-161.[4］ Valle Jimenez M, Estepa RM, Camacho RM, et al. Endothelial dysfunction is related to insulin resistance and inflammatory biomarker levels in obese prepubertal children［J］. Eur J Endocrinol, 2007, 156(4):497-502.［5］ Wannamethee SG, Lowe GD, Shaper AG, et al. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men［J］. Atherosclerosis, 2005, 181(1):101-108.［6］ Pedrinelli R, Giampietro O, Carmassi F, et al. Microalbuminuria and endothelial dysfunction in essential hypertension［J］. Lancet, 1994, 344(8914):14-18.［7］ Iyer SN, Katovich MJ. Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats［J］. Am J Hypertens, 1996, 9(7):662-668.［8］ Ortlepp JR, Breuer J, Eitner F, et al. Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia［J］. Eur J Pharmacol, 2002, 436(1-2):145-150.［9］ Flammer AJ, Hermann F, Wiesli P, et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension［J］. J Hypertens, 2007, 25(4):785-791.［10］刑绣荣，华琦，刘荣坤. 氯沙坦对高血压病患者血管内皮功能的影响及其临床意义［J］. 心脏杂志, 2007, 19(2):182-184,188.
备注/Memo
- 备注/Memo:
- 收稿日期：2008-1-10.通讯作者：金争鸣，主任医师，主要从事心血管疾病诊治研究Email：jzm57@163.com 作者简介：高佳儿，硕士生Email：jiaer_82@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed1562
- 评论/Comments
